Plasticell is a biotechnology company that develops novel therapies through precise control of stem cells and more differentiated cell types using award-winning combinatorial screening technology. We focus on manipulating pluripotent and haematopoietic cells to develop products for cancer and rare disease indications.
We are advancing a number of therapeutic programs, including the expansion of hematopoietic stem cells from bone marrow and cord blood, and the development of allogeneic immunotherapies, red blood cells and platelets from induced pluripotent stem cells (iPSCs).
Our combinatorial screening technology, CombiCult®, allows us to test large numbers of cell culture variables to derive optimal laboratory protocols for any given outcome in cell biology, including cell expansion and differentiation, gene transduction and protein production, as well as the provision of human cells for drug screening.
Plasticell collaborates with leading universities and industry partners to facilitate discovery and improve product manufacturing in a variety of high value areas such as cell therapy, gene therapy, cancer immunotherapy and drug discovery.